Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), retaining the price target ...

We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed 583.7% in 2024, according to data from S&P Global Market ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...